Subscribe to access the full database, or Start Trial
Tradename	Generic Name
METHOTREXATE	methotrexate
JYLAMVO	methotrexate
OTREXUP	methotrexate
OTREXUP PFS	methotrexate
RASUVO	methotrexate
>Tradename	>Generic Name

Last updated: April 25, 2026

What drugs sit inside ATC L01BA and how does the market behave?

ATC L01BA is the antineoplastic class for “Folic acid analogues.” In practice, the class is dominated by classic antifolates and their drug-product evolution, with methotrexate as the economic anchor and pemetrexed as the primary high-value growth compound tied to solid tumors. Other folate-pathway inhibitors appear as smaller contributors or regionally limited entrants depending on formulation and label breadth.

Core commercial actives typically attributed to L01BA

Active (ATC)	Typical positioning	Key market dynamic
Methotrexate (antifolate)	Broad oncology and off-label ecosystem	Patent timing is often fragmented by formulation, route, and geography; generics dominate long-run price erosion
Pemetrexed (antifolate)	Solid tumors (combination regimens)	Product lifecycle shaped by patent families around the active use, salt/form, and combination regimens
Other folate analogs	Smaller share; label- and region-dependent	Usually less influential for class-wide pricing than methotrexate and pemetrexed

Demand drivers

Combination oncology regimens: antifolates are used within multi-drug schedules; penetration depends on guideline inclusion, dosing convenience, and manageability of toxicity profiles.
Biosimilar-style competition does not apply: these are small molecules, so competition is generic and formulation-based, not biologics replication.
Cost pressure and tendering: methotrexate’s price is highly sensitive to generic procurement; pemetrexed sees tender competition in countries after exclusivity, but uptake stays regimen-driven.

How does pricing and competition typically evolve in L01BA?

Methotrexate: generic-led erosion, lifecycle fragmentation

Once originator exclusivity ends, multiple generics enter quickly across many countries.
Pricing settles based on tendering and pack size rather than clinical differentiation.
Patent strategy for the original product often shifts earlier toward formulation/process and method-of-use improvements (where granted), which may slow entry only in limited markets.

Pemetrexed: higher value, exclusivity extensions, and regimen dependence

Pemetrexed maintains pricing for longer due to:
- Patent coverage extending by use and combination claims (where allowed).
- Strong regimen dependence in oncology lines.
After exclusivity, competition concentrates on regimen interchangeability and supply continuity, not on innovation in mechanism.

What is the patent landscape pattern across the class?

For L01BA, the patent “shape” typically shows:

Early-life breadth from foundational molecule and composition claims.
Mid-life extensions via:
- Salt/formulation claims (where relevant for the commercial form)
- Process patents
- Method-of-use patents tied to specific tumor types, stages, or combinations
Late-life claim thinning: once broad claims are invalidated or expire, remaining coverage tends to narrow to specific instructions, dosing, or combination protocols.

What are the dominant IP families by economic relevance?

Methotrexate: lifecycle pressure and formulation/process governance

Key commercial reality:

Methotrexate is off-patent in most mature markets.
The patent landscape is less about new entrants and more about:
- Continuing control of niche formulation IP where it exists
- Country-specific barriers created by remaining process or formulation patents
- Brand-specific packaging and method-of-use claims that can persist longer in some jurisdictions

Business implication:

New development in methotrexate usually focuses on:
- Delivery enhancements
- Improved tolerability via supportive regimens
- New patient selection frameworks
For investors, the expected return profile is lower unless a meaningful clinical delta is secured.

Pemetrexed: combinations and use claims are the main battleground

Key commercial reality:

Pemetrexed’s value is tied to oncology regimens where claim validity and label alignment matter.
Patent enforcement commonly tracks to:
- New use populations
- Specific combination partners
- Dosing schedules and supportive therapy elements

Business implication:

The highest probability of payoffs typically sits in:
- Line-of-therapy expansions
- Combination optimization supported by clinical endpoints
- Second-generation formulations that create new IP while avoiding simple generic substitution barriers

Where are the main non-molecule competitive wedges?

Supportive care co-impacts

Folate analogs depend on supportive care (for example, leucovorin rescue patterns for antifolates and vitamin supplementation strategies). That creates an IP-adjacent competitive wedge:

Even when drug-product exclusivity falls, supportive regimens and label claims can shape prescriber behavior.
Combination regimens can maintain brand advantage if regimen-specific evidence supports a particular dosing choreography.

Formulation and administration convenience

Non-innovator entry often depends on:

Stability and shelf-life for the marketed form
Administration constraints (infusion times, reconstitution steps)
Supply chain reliability for tender contracts

How does regulatory exclusivity interact with the patent portfolio?

In folate analog oncology products:

Market exclusivity frequently overlaps with patent protection windows, but the binding constraint often becomes the patent set that blocks generic approval or triggers litigation.
Once patents expire, regulatory pathways can accelerate generic substitution, especially in markets with:
- Fast-track generic review capacity
- Procurement systems that prioritize lowest-cost equivalent formulations

What should a patent due diligence map look like for L01BA?

A practical landscape for diligence in this class focuses on:

Core substance and composition claims
Specific use and combination claims relevant to labeled regimens
Formulation/process claims that could block “skinny” generic substitutions
Method-of-treatment claims tied to patient selection, lines of therapy, or dosing schedules

Claim-scoping checklist (what matters in enforcement)

Claim type	Why it blocks competition	Typical weak points
Composition/substance	Blocks generic active ingredient or equivalent composition	Obviousness and breadth disputes
Method-of-use	Blocks generic prescribing by label or claim construction	Claim interpretation and prior art
Combination regimens	Keeps branded regimen dominant	Obviousness and obvious combinations
Formulation/process	Blocks an equivalent product entry	Narrow scope and experimental differences

Key market dynamics that shape post-expiry substitution

Regimen lock-in: if guidelines specify a combination with the antifolate, substitution can lag even after drug exclusivity ends.
Tender contracting: tends to drive faster generic uptake than pure clinical preference.
Toxicity management consistency: providers standardize supportive regimens tied to a specific antifolate protocol; switching is easier when the label and evidence align.

Patent landscape implications by strategic posture

For originators or in-licensors: where value accrues

The most robust late-stage value comes from use and combination patents that stay enforceable across key jurisdictions and cover the majority of reimbursed regimens.
Second-generation opportunities are highest where they:
- Expand into a new line or tumor subset with distinct clinical endpoints
- Create a unique formulation or dosing workflow tied to a specific protocol

For generics: where entry risk is concentrated

Generic entrants focus on:
- Patent listings mapped to the commercial indication and dosing regimen
- Whether remaining claims are method-of-use or formulation claims that can force design-around
Entry risk rises when:
- Remaining claims are tied to the reimbursed label indication rather than off-label contexts
- Combination patents are enforced and not easily invalidated

For developers of follow-on antifolates: what tends to succeed

Differentiation typically needs:
- Demonstrated clinical benefit in overall survival, response durability, or a validated surrogate that directly maps to guideline endpoints
- A pathway to claim coverage that is more than a minor dosing tweak
Otherwise, the class is crowded with off-patent molecules and rapid generic competition.

Key Takeaways

L01BA is dominated economically by methotrexate and pemetrexed, with market dynamics driven by generic erosion for methotrexate and regimen-driven value for pemetrexed.
Patent value concentrates in method-of-use and combination claims for pemetrexed-like products, while methotrexate’s landscape is mostly post-expiry with residual, jurisdiction-specific formulation or process issues.
Substitution after exclusivity depends on tendering and regimen lock-in, not just on molecule patent expiry.
Effective diligence for L01BA centers on mapping substance/composition, use, combination, and formulation/process claims to actual reimbursed protocols.

FAQs

Which antifolates matter most inside ATC L01BA by commercial impact?

Methotrexate and pemetrexed dominate the economic relevance of the folic acid analogue segment, with smaller contributions from other folate-pathway agents that vary by region and label availability.

What type of patents most often control competition for pemetrexed in key markets?

Method-of-use and combination regimens typically form the highest leverage portion of the patent portfolio, especially where they align with reimbursed oncology indications.

Why does methotrexate pricing fall quickly after exclusivity?

Generic entry plus procurement-driven tendering accelerates price erosion, and the molecule’s broad off-patent availability limits differentiation opportunities.

Does supportive care affect how quickly brands lose share after patent expiry?

Yes. Supportive regimen standardization and label-aligned rescue or supplementation protocols can slow switching even when the drug product exclusivity ends.

What is the practical due diligence focus when evaluating an L01BA entry or investment?

Map patent coverage to the marketed indication, dosing regimen, and combination protocol, then assess whether remaining claims are substance/composition, method-of-use, combination, or formulation/process.

References

[1] European Medicines Agency (EMA). ATC classification information for antineoplastic folic acid analogues (L01BA). https://www.ema.europa.eu/en
[2] World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: L01BA Folic acid analogues. https://www.whocc.no/atc_ddd_index/

Drugs in ATC Class L01BA

Drugs in ATC Class: L01BA - Folic acid analogues

Market dynamics and patent landscape for ATC Class L01BA - Folic acid analogues